David Bharucha bought $47k of MIST
Chief Medical Officer at Milestone Pharmaceuticals Inc.. 10,000 shares at an average of $4.74, traded Dec 1, 2022, filed Dec 5, 2022.
Score components
- +15RoleOfficer
- +6Trade size$47k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context49% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-22-059720, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2022 | POpen-market purchase Common Shares | +3,000 | $4.86 | $15k | 3,000 | Dec 5, 2022 |
| Dec 5, 2022 | POpen-market purchase Common Shares | +7,000 | $4.69 | $33k | 10,000 | Dec 5, 2022 |
Related signals
Other insiders at Milestone Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Milestone Pharmaceuticals Inc. | Joseph Oliveto President and CEO | $82k 36,500 shares | -8% | |
| 36Weak | Milestone Pharmaceuticals Inc. | David Bharucha Chief Medical Officer | $158k 70,252 shares | -43% | |
| 43Moderate | Milestone Pharmaceuticals Inc. | Amit Hasija CFO & EVP of Corp. Development | $158k 70,252 shares | -47% | |
| 51Moderate | Milestone Pharmaceuticals Inc. | Joseph Oliveto President and CEO | $375k 167,577 shares | -29% | |
| 36Weak | Milestone Pharmaceuticals Inc. | Lorenz Muller Chief Commercial Officer | $146k 64,746 shares | -26% | |
| 51Moderate | Milestone Pharmaceuticals Inc. | Jeffrey Edward Nelson Chief Operating Officer | $158k 70,252 shares | -70% | |
| 20Weak | Milestone Pharmaceuticals Inc. | Joseph Oliveto President and CEO | $98k 43,500 shares | -13% | |
| 54Moderate | Milestone Pharmaceuticals Inc. | Debra K. Liebert director | $74k 14,000 shares | - | |
| 55Moderate | Milestone Pharmaceuticals Inc. | Michael John Tomsicek director | $80k 15,000 shares | - | |
| 53Moderate | Milestone Pharmaceuticals Inc. | Richard C Pasternak director | $52k 10,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.